- [Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus<p>This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.</p>BioPharma Dive · 6h ago↗ source
- AstraZeneca looks to AI to ease risk in late-stage trials, speed up filingsAstraZeneca’s use of AI in drug design and development has not yet yielded any clinical-stage candidates, CEO Pascal Soriot said Monday, but he added it could be useful in boosting the success of l…Endpoints · 7h ago↗ source
- Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare diseaseAstraZeneca said Monday that a key late-stage trial of its Claudin 18.2-targeting ADC in stomach cancer had succeeded, albeit with a caveat — but another Phase 3 trial of Ultomiris yielded subpar r…